Dr. Belén Peral´s research group has been awarded with the FSEEN 2018 PRIZE

Dr. Belén Peral´s research group has been awarded with the FSEEN 2018 PRIZE  (Spanish Society of Endocrinology and Nutrition) to the best article published in the field of Obesity and Metabolic Syndrome.    In recent years, ageing-associated diseases, including obesity and type 2 diabetes, have been increasingly associated with mitochondrial dysfunction. However, the impact of these conditions on adipose tissue mitochondria remained to be elucidated. Dr. Belén Peral, a biochemist from the Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM (Madrid, Spain) has led a multidisciplinary team that included physicians from two hospitals (Clínico San Carlos and Gregorio Marañón, both from Madrid) and the Laboratory of Cardiovascular Proteomics at the Centro Nacional de Investigaciones Cardiovasculares (CNIC, Madrid),...

Our Masters included in the first places of the 250 Best Masters Ranking 2018 Edition.

The masters given by the Biochemistry Department and the Molecular Biology Department at the UAM are included again in the 250 Best Masters Ranking by the newspaper El Mundo. In this new 2018 edition, the  masters in Biomolecules and Cellular Dynamic  and in Molecular Biomedicine  have  the first and second places, respectively, within the Bioscience area, while the Biotechnology Master is the number one in the speciality of Biotechnology. A basic aspect of the teaching of these masters is the collaboration with the researchers from the IIBM centre (UAM-CSIC), which gives the students the opportunity of being taught in an investigation environment.

Dr. Gema Pérez was awarded with Professor Durantez - Foundation L.A.I.R. prize for the best article in the field of immunology carried out in a Spanish laboratory.

On February 15, the Lair Foundation celebrated its 25 th  anniversary. The Lair Foundation is dedicated to the promotion of immunology research and education. Among other activities, the Lair Foundation sponsors the Lair-UAM educational chair. During the ceremony, the 2017 Lair awards were presented.  The Professor Durantez prize for the best article in the field of immunology carried out in a Spanish laboratory was awarded to Gema Pérez Chacón, a member of Juan Manuel Zapata´s group at IIBm, for the work entitled "Indole- 3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances, "published in Clinical Cancer Research ( Clin Cancer Res.  2016 Jan 1; 22 (1): 134-45). Follow  us on Twitter!

"Constantes y Vitales" Award for the Best Scientific Trajectory goes to Dr Gabriela Morreale de Castro

In the 3rd edition of the awards promoted by "la Sexta"'s corporate responsibility campaign, together with the AXA Foundation, the "Constantes y Vitales" Award for the Best Scientific Trajectory has been awarded to our colleague Dr Gabriela Morreale de Castro , for her multiple contributions to the scientific field related to Endocrinology, especially the role of iodine and thyroid hormones in the development of the fetal and infant brain. The award was presented on October 26 at the Palacio de Neptuno in Madrid by the Secretary of State for Research, Innovation and Development, Ms. Carmen Vela. ATRESMEDIA link    

A researcher from the Neurobiology of Hearing group participates in a clinical trial of a new treatment for hereditary angioedema

Dr. Maria Luisa Baeza from the Neurobiology of Hearing group has participated in a Phase III clinical study ((EudraCT 2013-000916-10, NCT01912456) to evaluate the efficacy and safety of the C-1 inhibitor CSL830 in the treatment of hereditary angioedema The results of this trial indicate that the subcutaneous administration of CSL830 decreases the number of attacks of hereditary angioedema per month, with the majority of patients presenting a low profile of side effects. This work has been published in the prestigious New England Journal of Medicine Longhurst et al. Prevention of Hereditary Angioedema Attacks with Subcutaneous C1-Inhibitor. NEJM 2017 Mar 23;376(12):1131-1140  

A new molecule evaluated by the Neurobiology of Hearing group, authorized by the FDA to conduct Phase 1 clinical trial

Biopharmaceutical Company Spiral Therapeutics, Inc. has obtained the authorization from the US Food and Drug Administration (FDA) to start in early 2018 of a phase 1 clinical trial with LPT99, a new molecule for the treatment of chemotherapy-induced hearing loss in pediatric patients. LPT99 is a small molecule with strong anti-apoptotic activity. LPT99 is administered transtympanically in a hydrogel formulation to effectively reach the hair cells in the inner ear. This molecule has confirmed to be safe and effective in the animal model tests carried out by the Neurobiology of Hearing group, within the framework of an agreement with that company that began in 2015 and continues today.    

Scientists from the IIBM “Alberto Sols” CSIC-UAM attempt to develop a new kind of immunotherapy to target the cancer stem cells in pancreatic cancer

 The group of Dr. Bruno Sainz Anding, Ramón y Cajal Investigator from the Department of Biochemistry at the Universidad Autónoma de Madrid, the Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) and the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), are working to develop new monoclonal antibodies that will help the immune system identify and attack pancreatic cancer, which currently lacks effective immunotherapy-based treatments.  The project recently received a research grant of 60,000 euros from the Pancreatic Cancer Association (ACANPAN) and the Spanish Association of Pancreatology (AESPANC). "We seek to take an important step forward in the development of new therapies against these tumors," explains Dr. Sainz, who recalls that...

An investigation by the Hearing Neurobiology group receives the FIAPAS 2017 Award

The Spanish Confederation of Families of Deaf People (FIAPAS) held the ceremony for the presentation of its Prize for Research in Hearing Deficiencies on Wednesday, July 5, chaired by Dolors Montserrat, Minister of Health, Social Services and Equality. One of the two award-winning researches in the Health Category is a study conducted by researchers at the Neurobiology of Hearing Laboratory, Alberto Sols Institute of Biomedical Research CSIC-UAM, led by Prof. Isabel Varela-Nieto. The work, entitled "Evaluation of new therapies for the prevention of sensorineural hearing loss", is signed by researchers Silvia Murillo-Cuesta, Lourdes Rodríguez de la Rosa, Teresa Rivera, Fernando García-Alcántara, Lorena Sanz and Isabel Varela-Nieto. In addition, members of the Otorhinolaryngology Service of the Príncipe de Asturias University Hospital (Alcalá...

Isabel Varela-Nieto, has been elected to become a member of the Federation of European Biochemical Societies (FEBS)

Prof. Isabel Varela-Nieto, group leader of the Neurobiology of Hearing laboratory at the IIBm, has been elected to become a member of the Federation of European Biochemical Societies (FEBS), Science and Society Committee for the next three years (2017-2021). This prestigious society is a charitable organization that has supported research and education in molecular life sciences over the last fifty years.

The first edition of the Auditory Neuroscience Summer School

The first edition of the Auditory Neuroscience Summer School took place 6-8 july in the UAM Department of Anatomy, and was attended by 21 students from 6 countries and 13 teachers, including international experts in preclinical trials and bioinformatics. This theoretical and practical course was organized by Prof. Carlos Avendaño (UAM), Prof. Isabel Varela-Nieto (CSIC), Silvia Murillo-Cuesta (CIBERER), Dr. Luis Lassaleta ("La Paz" University Hospital) and Dr. Esperanza Bas (Ear Institute, University of Miami), sponsored by the Marie Curie FP7-PEOPLE-TARGEAR network and with the support of CIBERER.